|What Caught Our Eye (WCOE) Each week, we take a closer look at the cancer policy articles, studies, and stories that caught our attention.|
In the ABIM Foundation’s blog post “Professionalism as a Means for Improvement,” Daniel Wolfson wrote about a method for implementing the Choosing Wisely recommendations that relies on behavioral economics and professionalism, rather than regulation or financial incentives.
A viewpoint piece in JAMA entitled “The Physician Payment Sunshine Act: Testing the Value of Transparency,” Sachin Santhakumar, and Eli Adashi described some of the implementation challenges and concerns about the data reported this fall under the Open Payments Program. The program, a topic of a panel discussion at a recent NCCS Cancer Policy Roundtable, reports payments by pharmaceutical companies to physicians. Despite the challenges, Santhakumar and Adashi concluded, “The OPP initiative must be viewed as the most potent antidote for potential conflicts of interest engendered by financial interactions between industry and the health care delivery enterprise. As such, it should be given the benefits of doubt and time.”
Finally, in a Forbes article, “Should The FDA Force Drug Makers To Discuss Their Clinical Trials?” former Pfizer executive John LaMattina advised pharmaceutical companies to have the Food and Drug Administration (FDA) review clinical trials protocols before beginning the trial to improve the chances a drug will be approved if the trial is successful. LaMattina said that requiring such review would be overkill, but concluded, “When it comes to avoiding FDA guidance, drug companies beware.”
|Post by Shelley Fuld Nasso.|